{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:58:52Z","timestamp":1781060332890,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["18B2821N"],"award-info":[{"award-number":["18B2821N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["BeLux Fellowship 2020"],"award-info":[{"award-number":["BeLux Fellowship 2020"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13266-x","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:56:29Z","timestamp":1776873389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of hepatitis B surface antibodies and hepatitis B exposure in Belgium: results from a nationwide population-based serosurvey"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8658-4742","authenticated-orcid":false,"given":"Arno","family":"Furquim d\u2019Almeida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5034-3595","authenticated-orcid":false,"given":"Philippe","family":"Beutels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2880-441X","authenticated-orcid":false,"given":"Kirsten","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1881-0637","authenticated-orcid":false,"given":"Niel","family":"Hens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8642-1249","authenticated-orcid":false,"given":"Pierre","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Theeten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0572-8741","authenticated-orcid":false,"given":"Thomas","family":"Vanwolleghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"13266_CR1","unstructured":"World Health Organisation. Global hepatitis report 2024. Geneva. Published 8 April 2024. https:\/\/iris.who.int\/handle\/10665\/376461"},{"issue":"2","key":"13266_CR2","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","volume":"83","author":"M Cornberg","year":"2025","unstructured":"European Association for the Study of the L, Cornberg M, Sandmann L, Jaroszewicz J, Kennedy P, Lampertico P, et al. EASL Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;83(2):502\u201383.","journal-title":"J Hepatol"},{"issue":"1","key":"13266_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/ueg2.12176","volume":"10","author":"A Furquim d\u2019Almeida","year":"2022","unstructured":"Furquim d\u2019Almeida A, Ho E, Van Hees S, Vanwolleghem T. Clinical management of chronic hepatitis B: a concise overview. United Eur Gastroenterol J. 2022;10(1):115\u201323.","journal-title":"United Eur Gastroenterol J"},{"issue":"5","key":"13266_CR4","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/apt.17120","volume":"56","author":"GL-H Wong","year":"2022","unstructured":"Wong GL-H, Hui VW-K, Yip TC-F, Liang LY, Zhang X, Tse Y-K, et al. Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma. Aliment Pharmacol Ther. 2022;56(5):869\u201377.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"13266_CR5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1053\/j.gastro.2016.05.048","volume":"151","author":"M-H Chang","year":"2016","unstructured":"Chang M-H, You S-L, Chen C-J, Liu C-J, Lai M-W, Wu T-C, et al. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. Gastroenterology. 2016;151(3):472\u2013e801.","journal-title":"Gastroenterology"},{"issue":"16","key":"13266_CR6","doi-asserted-by":"publisher","first-page":"e19886","DOI":"10.1097\/MD.0000000000019886","volume":"99","author":"Z Chen","year":"2020","unstructured":"Chen Z, Zeng M, Liu D, Wu L, Zhang L. Antenatal administration of hepatitis B immunoglobulin and hepatitis B vaccine to prevent mother to child transmission in hepatitis B virus surface antigen positive pregnant women: A systematic review and meta-analysis. Medicine. 2020;99(16):e19886.","journal-title":"Medicine"},{"key":"13266_CR7","unstructured":"World Health Organisation. Guidance for country validation of viral hepatitis elimination and path to elimination. Geneva. Published 5. October 2023. https:\/\/iris.who.int\/handle\/10665\/373186"},{"issue":"3","key":"13266_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1023\/A:1007393405966","volume":"13","author":"M Beutels","year":"1997","unstructured":"Beutels M, Van Damme P, Aelvoet W, Desmyter J, Dondeyne F, Goilav C, et al. Prevalence of hepatitis A, B and C in the flemish population. Eur J Epidemiol. 1997;13(3):275\u201380.","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"13266_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10654-007-9105-6","volume":"22","author":"S Quoilin","year":"2007","unstructured":"Quoilin S, Hutse V, Vandenberghe H, Claeys F, Verhaegen E, De Cock L, et al. A population-based prevalence study of hepatitis A, B and C virus using oral fluid in Flanders, Belgium. Eur J Epidemiol. 2007;22(3):195\u2013202.","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"13266_CR10","doi-asserted-by":"publisher","first-page":"2500533","DOI":"10.2807\/1560-7917.ES.2026.31.6.2500533","volume":"31","author":"A Furquim d\u2019Almeida","year":"2026","unstructured":"Furquim d\u2019Almeida A, Ho E, Sch\u00fcttler C, Beutels P, Hens N, Dudareva S, et al. Combined HBsAg and anti-HBc testing is required to estimate hepatitis B virus seroprevalence in a low-endemic country: findings from a nationwide population-based serosurvey, Belgium, 2020. Eurosurveillance. 2026;31(6):2500533.","journal-title":"Eurosurveillance"},{"key":"13266_CR11","unstructured":"Grammens T, Cornelissen L, Vaccinatiegraad. Sciensano. 2021."},{"key":"13266_CR12","doi-asserted-by":"crossref","unstructured":"Herzog SA, De Bie J, Abrams S, Wouters I, Ekinci E, Patteet L et al. Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020. Eurosurveillance. 2022;27(9).","DOI":"10.2807\/1560-7917.ES.2022.27.9.2100419"},{"issue":"1","key":"13266_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1214\/aos\/1176346391","volume":"12","author":"JNK Rao","year":"1984","unstructured":"Rao JNK, Scott AJ. On Chi-squared tests for multiway contingency tables with cell proportions estimated from survey data. Annals Stat. 1984;12(1):46\u201360.","journal-title":"Annals Stat"},{"key":"13266_CR14","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2024","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2024."},{"issue":"2","key":"13266_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S2468-1253(16)30076-0","volume":"2","author":"Q Wang","year":"2017","unstructured":"Wang Q, Klenerman P, Semmo N. Significance of anti-HBc alone serological status in clinical practice. Lancet Gastroenterol Hepatol. 2017;2(2):123\u201334.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"13266_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1017\/S0950268813001064","volume":"142","author":"H Theeten","year":"2014","unstructured":"Theeten H, Hutse V, Hoppenbrouwers K, Beutels P. Universal hepatitis B vaccination in Belgium: impact on serological markers 3 and 7 years after implementation. Epidemiol Infect. 2014;142(2):251\u201361.","journal-title":"Epidemiol Infect"},{"key":"13266_CR17","unstructured":"Migration census. 2021. STATBEL. Accessed 11 February 2026 https:\/\/statbel.fgov.be\/en\/themes\/census\/population\/migration"},{"key":"13266_CR18","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1017\/S0950268819000359","volume":"147","author":"J Koopsen","year":"2019","unstructured":"Koopsen J, van Steenbergen JE, Richardus JH, Prins M, Op de Coul ELM, Croes EA, et al. Chronic hepatitis B and C infections in the Netherlands: estimated prevalence in risk groups and the general population. Epidemiol Infect. 2019;147:e147.","journal-title":"Epidemiol Infect"},{"key":"13266_CR19","doi-asserted-by":"publisher","first-page":"1471256","DOI":"10.3389\/fpubh.2025.1471256","volume":"13","author":"K Kremer-Flach","year":"2025","unstructured":"Kremer-Flach K, Zimmermann R, An der Heiden M, Dudareva S. Estimated number of people infected with hepatitis B and C virus in Germany in 2013: a baseline prevalence estimate using the workbook method. Front Public Health. 2025;13:1471256.","journal-title":"Front Public Health"},{"issue":"1","key":"13266_CR20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.5334\/aogh.2848","volume":"86","author":"E Ho","year":"2020","unstructured":"Ho E, Michielsen P, Van Damme P, Ieven M, Veldhuijzen I, Vanwolleghem T. Point-of-care tests for hepatitis B are associated with a higher linkage to care and lower cost compared to venepuncture sampling during outreach screenings in an asian migrant population. Annals Global Health. 2020;86(1):81.","journal-title":"Annals Global Health"},{"issue":"1","key":"13266_CR21","doi-asserted-by":"publisher","first-page":"100369","DOI":"10.1016\/j.jve.2024.100369","volume":"10","author":"E Ho","year":"2024","unstructured":"Ho E, Vanderlinden A, Govaerts L, De Fooz B, Van Damme P, Michielsen P, et al. Opportunistic screening using point-of-care testing leads to successful linkage to care of HBV-infected migrant populations in a low endemic country. J Virus Eradication. 2024;10(1):100369.","journal-title":"J Virus Eradication"},{"issue":"1","key":"13266_CR22","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12879-024-09201-7","volume":"24","author":"I Sperle","year":"2024","unstructured":"Sperle I, Lassen SG, Schlaud M, D\u00f6rre A, Dudareva S, Poethko-M\u00fcller C, et al. Prevalence of vaccine-derived hepatitis B surface antibodies in children and adolescents in Germany: results from a population-based survey, 2014\u20132017. BMC Infect Dis. 2024;24(1):318.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"13266_CR23","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/21645515.2017.1264795","volume":"13","author":"L Roman\u00f2","year":"2017","unstructured":"Roman\u00f2 L, Galli C, Tagliacarne C, Tosti ME, Velati C, Fomiatti L, et al. Persistence of immunity 18\u201319 years after vaccination against hepatitis B in 2 cohorts of vaccinees primed as infants or as adolescents in Italy. Hum Vaccines Immunotherapeutics. 2017;13(5):981\u20135.","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"13266_CR24","unstructured":"European Centre for Disease Prevention and Control. Hepatitis B vaccination policies, practices and challenges to achieving hepatitis elimination in the European Union and European Economic Area. Stockholm. 2025."},{"issue":"1","key":"13266_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/cid\/cir270","volume":"53","author":"E Leuridan","year":"2011","unstructured":"Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis. 2011;53(1):68\u201375.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"13266_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/infdis\/jiw142","volume":"214","author":"BC Simons","year":"2016","unstructured":"Simons BC, Spradling PR, Bruden DJ, Zanis C, Case S, Choromanski TL, et al. A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B virus (HBV) cellular immunity despite loss of antibody against HBV surface antigen. J Infect Dis. 2016;214(2):273\u201380.","journal-title":"J Infect Dis"},{"issue":"5","key":"13266_CR27","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1080\/21645515.2016.1274473","volume":"13","author":"P Van Damme","year":"2017","unstructured":"Van Damme P, Leroux-Roels G, Suryakiran P, Folschweiller N, Van Der Meeren O. Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine. Hum Vaccines Immunotherapeutics. 2017;13(5):972\u201380.","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"13266_CR28","doi-asserted-by":"crossref","unstructured":"Cocchio S, Baldo V, Volpin A, Fonzo M, Floreani A, Furlan P et al. Persistence of anti-Hbs after up to 30 years in health care workers vaccinated against hepatitis B virus. Vaccines (Basel). 2021;9(4).","DOI":"10.3390\/vaccines9040323"},{"key":"13266_CR29","unstructured":"World Health Organisation. Regional action plans for ending AIDS and the epidemics of viral hepatitis and sexually transmitted infections 2022\u20132030. Copenhagen. Published 14 June 2023. https:\/\/iris.who.int\/handle\/10665\/369243"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13266-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13266-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13266-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:27:28Z","timestamp":1781058448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13266-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13266"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13266-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. Ethical committee approval for this study and the re-use of the samples was obtained from the University of Antwerp \u2013 Antwerp University Hospital Ethical Committee (reference 21\/02\/021 and 6712). The original SARS-CoV-2 study was approved by the Ethical Committee of the University of Antwerp \u2013 Antwerp University Hospital (reference 20\/13\/158). The requirement of informed consent was waived by the University of Antwerp \u2013 Antwerp University Hospital Ethical committee because the study involved secondary use of anonymized leftover serum samples.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Thomas Vanwolleghem has received grants from Gilead Sciences and Fujirebio, served as a consultant for Janssen Pharmaceuticals, Gilead Sciences, AbbVie, and has served as a sponsored lecturer for Gilead Sciences, Roche and AbbVie. All other authors have nothing to disclose in relation to this research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1097"}}